Our Solid Tumor Program is made up of medical and research professionals dedicated to treating solid tumors and developing new treatments and cures for the future. We care for more than 150 newly diagnosed patients with these forms of cancer each year.
Our program:
- Is home to one of the top 131I-MIBG programs in the country, treating more than 65 children with relapsed or refractory neuroblastoma over the past five years.
- Coordinates care with a team of pediatric specialists, including oncology, radiation oncology, general surgery, orthopaedic surgery and rehabilitation.
- Includes physicians with national leadership roles in the areas of neuroblastoma, germ cell tumors and retinoblastoma.
- Offers expertise in rare tumors and adult-like cancers occurring in pediatric patients, with strong collaboration with our adult cancer center partner, the NCI-designated Winship Cancer Institute.
- Has one of the largest comprehensive orthopaedic oncology programs in the Southeast, with dedicated pediatric oncologists, radiation oncologists and orthopaedic oncologists. Serves as a leading referral center for retinoblastoma in the Southeast, with participation in limited institution clinical research studies.
- Recently procured NIH and NCI funding (R21) to test novel engineered gamma delta T cell immunotherapy in patients with neuroblastoma.
Click the links below for more information about our Solid Tumor Program and research.
Our solid tumor team:
- Thomas Cash, MD, MSc, Medical Director
- Bradley George, MD
- Kelly Goldsmith, MD
- Andrew Hong, MD
- Sarah Mitchell, MD
- Thomas Olson, MD, Program Medical Director
- Kathryn Sutton, MD
- Karen Wasilewski-Masker, MD, MSCR